Squalamine (黃斑部水腫·黃斑部病變) :預測·市場分析
Squalamine (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 111 Pages
|Squalamine (黃斑部水腫·黃斑部病變) :預測·市場分析 Squalamine (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023|
|出版日期: 2014年10月31日||內容資訊: 英文 111 Pages||
Squalamine (Squalamine lactate)是Ohr Pharmaceuticals開發的 滲出型AMD (乾燥型老年性黃斑部病變)用之眼藥水劃時代醫藥品 (First-in-Class) 。這個小分子藥劑具有新的細胞內作用機制，並可強力抑制包含VEGF、PDGF、及bFGF的複數蛋白質成長因子。
Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.
Squalamine (Squalamine lactate) is a first-in-class drug being developed by Ohr Pharmaceuticals as a novel eye drop solution treatment for wAMD. This small-molecule drug has a novel intracellular mechanism of action and can potently inhibit multiple protein growth factors involved in angiogenesis, including VEGF, PDGF, and bFGF.